Literature DB >> 3562443

Plasma cholecystokinin concentrations in patients with advanced chronic pancreatitis.

P Cantor, L Petronijevic, H Worning.   

Abstract

Plasma concentrations of cholecystokinin (CCK) have been reported to be elevated in patients with chronic pancreatitis. The elevations are suggested to be due to increased release of CCK from the upper small intestine secondary to the absence of protease activity (trypsin and chymotrypsin) in the intestinal lumen. We have studied plasma CCK levels before and after liquid as well as solid meals in eight patients with pancreatic insufficiency due to advanced chronic pancreatitis and in eight healthy controls. CCK concentrations were measured with a sensitive and specific radioimmunoassay using an antibody directed against the sulfated tyrosyl region of CCK. No differences in basal or maximal postprandial plasma CCK levels between patients and controls were observed. In the liquid meal study, basal CCK concentrations in patients and controls were 2.2 +/- 0.7 and 2.5 +/- 0.4 pM, respectively, with maximal postprandial concentrations of 9.6 +/- 2.2 and 11.2 +/- 1.4 pM. In the solid meal study, basal CCK concentrations in patients and controls were 2.5 +/- 0.6 and 2.6 +/- 0.4 pM, respectively, with maximal postprandial concentrations of 9.4 +/- 1.6 and 8.6 +/- 1.4 pM. The only difference observed was a significantly longer time interval to maximal plasma CCK levels in patients as compared with controls after the liquid meal. Two patients with no detectable trypsin activity in the small intestinal lumen during a Lundh test meal had basal CCK levels of 1.3 and 1.8 pM. Thus, the present study does not support the hypothesis that trypsin is involved in the regulation of CCK release.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3562443     DOI: 10.1097/00006676-198611000-00004

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man.

Authors:  J B Jansen; M C Jebbink; B R Douglas; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency.

Authors:  T Nakamura; K Takebe; K Kudoh; M Ishii; K Imamura; H Kikuchi; F Kasai; Y Tandoh; N Yamada; Y Arai
Journal:  Int J Pancreatol       Date:  1995-02

3.  Postprandial cholecystokinin response in patients with chronic pancreatitis in treatment with oral substitutive pancreatic enzymes.

Authors:  M C Garcés; J Gómez-Cerezo; R Codoceo; C Grande; J Barbado; J J Vázquez
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

4.  Gastrin-releasing peptide and CCK after intraduodenal inhibition of proteases in dogs.

Authors:  R Nustede; W E Schmidt; M Jäger; F Stöckmann; H Köhler; U R Fölsch; H J Peiper
Journal:  Int J Pancreatol       Date:  1994-06

5.  Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.

Authors:  K Miyasaka; A Funakoshi; A Jimi; R Nakamura; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

6.  Reversible gall bladder dysfunction in severe pancreatic insufficiency.

Authors:  A A Masclee; J B Jansen; F H Corstens; C B Lamers
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

7.  Influence of treatment with pancreatic extracts on pancreatic enzyme secretion.

Authors:  J Mössner; H P Wresky; W Kestel; J Zeeh; U Regner; W Fischbach
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

8.  Oleic acid ameliorates palmitic acid-induced ER stress and inflammation markers in naive and cerulein-treated exocrine pancreas cells.

Authors:  Karin Ben-Dror; Ruth Birk
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.